$5.96 Billion in Sales Expected for Eli Lilly and Co (LLY) This Quarter

Wall Street analysts expect Eli Lilly and Co (NYSE:LLY) to post $5.96 billion in sales for the current quarter, Zacks reports. Four analysts have made estimates for Eli Lilly and’s earnings. The lowest sales estimate is $5.89 billion and the highest is $6.04 billion. Eli Lilly and reported sales of $5.76 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 3.5%. The company is expected to issue its next quarterly earnings report on Tuesday, January 30th.

According to Zacks, analysts expect that Eli Lilly and will report full-year sales of $5.96 billion for the current financial year, with estimates ranging from $22.60 billion to $22.71 billion. For the next financial year, analysts anticipate that the business will report sales of $23.19 billion per share, with estimates ranging from $23.05 billion to $23.32 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Eli Lilly and.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter last year, the company earned $0.88 earnings per share. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year.

A number of brokerages recently weighed in on LLY. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 12th. Morgan Stanley raised their price target on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 21st. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Berenberg Bank reissued a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Thursday, October 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $90.25.

Shares of Eli Lilly and (NYSE:LLY) opened at $85.14 on Thursday. Eli Lilly and has a 12-month low of $74.00 and a 12-month high of $89.09. The firm has a market capitalization of $93,240.73, a PE ratio of 40.35, a P/E/G ratio of 1.59 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.64%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 251,088 shares of company stock valued at $22,041,236. Company insiders own 0.20% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Pathstone Family Office LLC raised its position in Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new position in Eli Lilly and during the second quarter valued at approximately $494,000. Acrospire Investment Management LLC raised its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new position in Eli Lilly and during the second quarter valued at approximately $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and during the second quarter valued at approximately $129,000. Hedge funds and other institutional investors own 76.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “$5.96 Billion in Sales Expected for Eli Lilly and Co (LLY) This Quarter” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/04/5-96-billion-in-sales-expected-for-eli-lilly-and-co-lly-this-quarter.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply